We are an innovative biotechnology company based in Scotland. Along with our in-house research and development team, we also have research collaborations in place with world renowned institutions and universities.
Since 2012, we’ve invested heavily in our own R&D capabilities to enable us to advance our pioneering research in nucleic acid transfer. Recently, we’ve moved into bespoke laboratories and offices, advancing the testing of active agent LAMELLASOME™ products (including nucleic acids) in in vitro cell models, CF infection models and significantly extending our formulation and processing capabilities.
Lamellar’s patent portfolio has recently expanded to include our promising new LAMELLASOME™ Nucleic Acid Transfer technology and some key products that demonstrate the potential of the technology.
Collaboration & partnerships
Lamellar are active members of the Scottish Life Sciences Association (SLA) and contribute to multiple special interest groups. This has included working with the SLA to directly lobby for the development of the life sciences sector with the Scottish Government.
Grants & awards
Together with Prof Perrie of Strathclyde University, we won an Innovate UK Knowledge Transfer Partnership award for the process optimisation and characterisation of LAMELLASOME™ formulations.
Lamellar and Edinburgh Complex Fluids Partnership of Edinburgh University won an Innovate UK award to develop LAMELLASOME™ properties for use in the treatment of CF.
Lamellar and the Roslin Institute won an MRS PhD studentship for the study of LAMELLASOME™ as an antifibrotic agent.
We have also been successful in attracting major grants to support our in-house research including SMART Scotland, NBIC award, MRS, SULSA, KTP and BBSRC iCase grants.